Skip to main content

Celularity Inc

corporate_fare Company Profile

Celularity Inc

CELU·NASDAQ·Life Sciences·CIK 0001752828

Celularity Inc is a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The company's objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life. Aging is a major risk factor for many degenerative disorders and diseases across multiple high-value therapeutic areas, including immunology and regenerative medicine. Common to all degenerative disorders and diseases is the progressive loss of function or structure (or both) of affected tissues and organs driven by underlying cellular dysfunction, which directly impacts regenerative capacity, healthspan and overall lifespan. Age-associated immunosenescence and other physiological changes contribute to increased vulnerability to infections, which further exacerbate aging-related decline and are increasingly associated with frailty and adverse clinical outcomes. Aging and longevity are determined by a complex combination of genetic, nongenetic, and environmental factors. While aging is not itself a disease, it increases vulnerability to disease and is among the most important known risk factors for most chronic diseases; for example, aging is a primary driver of cancer and other chronic conditions. The accumulation of senescent cells in aged tissues is suggested to be a key factor underlying age-related cancer, and age is a key risk factor for autoimmune disease, with many autoimmune diseases preferentially occurring in the second half of adulthood as immune function declines. These processes are increasingly linked to age-related immune dysregulation. Aging is associated with a progressive degeneration of tissues, resulting in significant impairment on the structure and function of vital organs. Chronic, low-grade systemic inflammation, often referred to as "inflammaging," is characterized by higher levels of circulating pro-inflammatory cytokines driven by cellular damage and senescent cell accumulation. Senescent cells contribute to disease progression by limiting the regenerative capacity of tissue stem cells and inducing the accumulation of cellular damage.

Celularity Inc (NASDAQ:CELU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for CELU at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Celularity Settles Default Claims with Helena for $1M Cash and $2.5M Note Assignment
  • Celularity Files 10-K, Regains Nasdaq Compliance, Highlights Strategic Shift
  • Major Investor Discloses 20.1% Potential Stake from Convertible Notes and Warrants
  • Celularity Faces Debt Default and Executive Departures Amidst Strategic Realignment and $13.3M Asset Sale
  • Major Investor Discloses 9.56% Stake in Celularity Inc. Following $10M Secured Financing and Board Observer Right

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$26.55M
Net Income
-$91.72M
Diluted EPS
-$3.59
Op. Cash Flow
-$13.25M
Gross Profit
$6.48M
Operating Income
-$61.31M
Cash & Equivalents
$6.17M
Debt / Equity
0.00×
Net Margin
-345.4%
Shares Outstanding
28.84M sh
Source: 10-K · filed 2026-04-30 · accession 0001493152-26-020424
$0.451 -2.59% today
52-week range · as of 2026-11-10 $0.451 – $2.55
Market cap
$15.02M
Volume
295.9K (1.7× avg)
3-mo avg 174.5K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CELU - Filings & News (Page 2)

CELU
May 28, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.991
Real-time Price: $0.451 info
Change: -$0.540 (-54%) info
Market Cap: $15.025M info
CELU
May 01, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.451 info
Change: -$0.5691 (-56%) info
Market Cap: $15.025M info
CELU
Apr 22, 2026, 10:16 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.22
Real-time Price: $0.451 info
Change: -$0.769 (-63%) info
Market Cap: $15.025M info
CELU
Apr 21, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $0.451 info
Change: -$0.759 (-63%) info
Market Cap: $15.025M info
CELU
Apr 03, 2026, 11:08 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $1.33
Real-time Price: $0.451 info
Change: -$0.879 (-66%) info
Market Cap: $15.025M info
CELU
Mar 10, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.29
Real-time Price: $0.451 info
Change: -$0.839 (-65%) info
Market Cap: $15.025M info
CELU
Mar 05, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.451 info
Change: -$0.749 (-62%) info
Market Cap: $15.025M info
CELU
Jan 21, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.451 info
Change: -$0.799 (-64%) info
Market Cap: $15.025M info
CELU
Jan 08, 2026, 6:15 AM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $0.451 info
Change: -$0.789 (-64%) info
Market Cap: $15.025M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets